Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Meta Expands AI Training With Employee Activity Tracking Tools 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced presentations at the following conferences taking place in April:
World Orphan Drug Congress USA, April 19 – 21 2017, at the Washington Marriott Wardman Park in Washington D.C.
- Matt Kapusta, Chief Executive Officer, will be presenting a keynote address: Adeno-associated virus (AAV)-based gene therapies for rare, chronic and degenerative diseases, on Friday April 21st, 2017, 9.40 a.m. EDT.
12th Annual HD Therapeutics Conference by CHDI, April 24 – 27 2017, at the Westin Dragonara Resort in St. Julian’s, Malta.
- A presentation new preclinical data on huntingtin gene silencing in a mini-pig model of Huntington’s Disease, using allele-specific and non-selective miRNAs, will be presented during the CHDI conference.
Gene Therapy for Rare Disorders Conference, April 25 – 26 2017, at the Sheraton Boston Hotel, in Boston MA.
- Lance Weed, Vice President of US Operations, will be presenting: Optimizing the Scalability of Gene Therapy Manufacturing, on Tuesday April 25th, 2017, 2.00 p.m. EDT.
- Eileen Sawyer, Director of Global Medical Affairs, will be presenting: Bridging Gaps Through Early Integration of the Internal Medical Affairs Function, on Wednesday April 26th, 2017, 11.00 a.m. EDT.
- Daniel Leonard, Director of Global Patient Advocacy, will be presenting: The Intersection of Patient Advocacy and Gene Therapy: A Case Study in Hemophilia, on Wednesday April 26th, 2017, 2.00 p.m. EDT.
Alliance for Regenerative Medicines (ARM)’s 5th Annual Cell & Gene Therapy Investor Day, April 27th 2017, at The State Room, in Boston MA.
- Matthew Kapusta, chief executive officer, will be participating in a fireside chat on Thursday, April 27th, 2017, 2.15 p.m. EDT.
The Company also announced its participation in the following conferences taking place in April:
Hemophilia Federation of America (HFA)’s Annual Symposium, April 6 – 9 2017, at the Rhode Island Convention Center in Providence, RI.
The International Liver Congress 2017 by EASL, April 19 – 23 2017 at the RAI in Amsterdam, The Netherlands.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected]
